US2012065258A1PendingUtilityA1

Stable prostaglandin-containing compositions

Assignee: DEACIUC VICTORPriority: Jan 20, 2005Filed: Nov 17, 2011Published: Mar 15, 2012

Est. expiryJan 20, 2025(expired)· nominal 20-yr term from priority

Inventors:Victor Deaciuc Michael Hagan Hashem Heiati Karen K. Jette Gary Conard Visor Ian G.C. Mcaffer Peter Ernest Tasko

A61P 27/02A61P 27/06A61K 9/0048A61K 31/215A61K 31/557

PatentIndex Score

Cited by

References

Claims

Abstract

A pharmaceutical composition containing a prostaglandin and an alkanoic acid ester of a polyethoxylated sorbitol in an amount effective to enhance the chemical stability of the prostaglandin, and the use thereof for treating ophthalmic conditions. Also disclosed are methods for enhancing the chemical stability of a prostaglandin-containing composition by using an alkanoic acid ester of a polyethoxylated sorbitol.

Claims

exact text as granted — not AI-modified

1 . A pharmaceutical composition consisting essentially of:
 (a) travoprost (II) at a concentration of 0.002% to 0.008% w/v;   (b) a monooleate ester of a polyethoxylated sorbitol at a concentration of 0.4 to 0.6% w/v; and   (c) a pharmaceutically acceptable carrier.   
     
     
         2 . A pharmaceutical composition according to  claim 1 , wherein the monooleate ester of a polyethoxylated sorbitol is present at a concentration of 0.5% w/v. 
     
     
         3 . A pharmaceutical composition according to  claim 1 , wherein the monooleate ester of a polyethoxylated sorbitol is polysorbate 80. 
     
     
         4 . A pharmaceutical composition according to  claim 1 , wherein the travoprost is present at a concentration of 0.004% w/v. 
     
     
         5 . A pharmaceutical composition according to  claim 1 , wherein the composition has a pH in the range 5.0 to 7.5. 
     
     
         6 . A pharmaceutical composition according to  claim 5 , wherein the pH is approximately 6.0. 
     
     
         7 . A pharmaceutical composition according to  claim 1  for topical applications. 
     
     
         8 . A pharmaceutical composition according to  claim 7  for use in the treatment of ocular hypertension. 
     
     
         9 . A pharmaceutical composition according to  claim 7  for use in the treatment of glaucoma.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.